UPS Healthcare is investing $48 million to build 27 temperature-controlled cross-dock facilities across the US, Europe, Asia and the Americas. All sites will be certified for pharmaceutical handling. The network targets the handoff between planes and trucks, one of the high-risk stages for temperature excursions in cold-chain shipping.
How it works: A cross-dock is a facility for short-term staging as goods move between air and ground transport. The goal is to maintain required temperature throughout the transfer. The new sites support three ranges including 2-8°C refrigerated, 15-25°C controlled room temperature, and frozen. Each site carries IATA CEIV Pharma certification, the industry standard for pharmaceutical handling.
Temperature excursions, meaning deviations from a drugs safe range, cost the industry as much as $35 billion a year in spoiled products. The World Health Organization estimates they account for up to half of global vaccine waste. The network builds on UPS’s prior cold-chain acquisitions including Bomi Group, Frigo Trans and Andlauer.
Why now: Biologics account for roughly one in three newly approved drugs, and more than 85% require temperature-controlled handling, according to PharmaSource. Demand for temperature-sensitive biologics is projected to grow at an annual rate of 8.3% to about $39.1 billion by 2033, according to Growth Market Reports. Cell and gene therapies, mRNA drugs, and GLP-1 injectables are driving much of that growth.
The freight also supports UPS’s broader network strategy as the company expects Amazon volume to decline by more than 50% by mid-2026 under its “better not bigger” cost program. UPS Healthcare generated about $3 billion in revenue in Q1, roughly 14% of company revenue, and remains on a previously stated path toward a $20 billion annual target.
Across the sector: DHL and FedEx are pursuing the same high-margin shift. DHL has committed about $2.2 billion and is targeting roughly $10.8 billion in healthcare revenue by 2030. FedEx is chasing about $9 billion.
What to watch: For UPS, pharma freight is helping refill the network space created by lower Amazon volumes. The revenue mix changes while the physical network stays largely the same. The key question is whether the cross-dock network can win clinical trial volume at scale. UPS Healthcare identifies clinical logistics as its highest-margin segment.
